GXO Logistics Inc vs Medtronic PLC — how do they compare? GXO Logistics Inc trades at $46.49 (market cap $5.32B), while Medtronic PLC trades at $88.41 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 21.1× GXO Logistics Inc's market cap, and Medtronic PLC pays a 3.28% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 28 Days and Medtronic PLC for 63 Days on average.
| GXO | MDT | |
|---|---|---|
Market Cap | $5.32B | $112.24B |
Volume | 1,255,816 | 105,663,236 |
Sector | Industrials | Health |
52-Week High | $65.59 | $105.35 |
52-Week Low | $44.17 | $73.75 |
Typical Hold Time | 28 Days | 63 Days |
Enterprise Value | $10.67B | $131.58B |
Dividend Yield | — | 3.28% |
Signals from Pluang's Aura AI — not financial advice
GXO trades at $46.58, up 1.28% today, with a neutral technical signal and strong analyst support. The company reported three consecutive quarterly EPS beats and is expanding through strategic partnerships, including a new 10-year logistics deal with Columbia Sportswear in Europe. Revenue grew to $13.18B in 2025, with a net income margin of 0.96%, though valuation metrics like a P/E of 41.03 appear elevated relative to profitability.
The outlook is positive, driven by operational improvements and industry tailwinds, but risks include margin pressures and high debt. With an 89% buy rating from analysts and a consensus price target of $66.67, the stock offers significant upside potential if execution aligns with growth initiatives.
Medtronic (MDT) trades at $87.80, up 2.68% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 13.93% net income margin and consistent dividend growth over 49 years. Revenue growth accelerated to $33.54B in 2025, and analyst consensus targets $97.80, implying 11% upside. Recent news highlights regulatory approvals for medical devices and a $4B MiniMed exchange offer.
MDT offers value with a 3.2% dividend yield and reasonable valuation (P/E 21.6), but faces headwinds from technical bearishness and rising debt. The stock's appeal hinges on execution of growth initiatives in cardiovascular and neuroscience segments, though competitive and macroeconomic risks persist.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →